Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, Amsterdam, The Netherlands.
PLoS One. 2012;7(7):e42179. doi: 10.1371/journal.pone.0042179. Epub 2012 Jul 31.
Remote ischemic conditioning is gaining interest as potential method to induce resistance against ischemia reperfusion injury in a variety of clinical settings. We performed a systematic review and meta-analysis to investigate whether remote ischemic conditioning reduces mortality, major adverse cardiovascular events, length of stay in hospital and in the intensive care unit and biomarker release in patients who suffer from or are at risk for ischemia reperfusion injury.
Medline, EMBASE and Cochrane databases were searched for randomized clinical trials comparing remote ischemic conditioning, regardless of timing, with no conditioning. Two investigators independently selected suitable trials, assessed trial quality and extracted data. 23 studies in patients undergoing cardiac surgery (15 studies), percutaneous coronary intervention (four studies) and vascular surgery (four studies), comprising in total 1878 patients, were included in this review. Compared to no conditioning, remote ischemic conditioning did not reduce mortality (odds ratio 1.22 [95% confidence interval 0.48, 3.07]) or major adverse cardiovascular events (0.65 [0.38, 1.14]). However, the incidence of myocardial infarction was reduced with remote ischemic conditioning (0.50 [0.31, 0.82]), as was peak troponin release (standardized mean difference -0.28 [-0.47, -0.09]).
There is no evidence that remote ischemic conditioning reduces mortality associated with ischemic events; nor does it reduce major adverse cardiovascular events. However, remote ischemic conditioning did reduce the incidence of peri-procedural myocardial infarctions, as well as the release of troponin.
远程缺血预处理作为一种在多种临床情况下诱导对缺血再灌注损伤的抵抗的潜在方法,正受到越来越多的关注。我们进行了一项系统回顾和荟萃分析,以调查远程缺血预处理是否可以降低死亡率、主要不良心血管事件、住院时间和重症监护病房时间以及发生或有缺血再灌注损伤风险的患者的生物标志物释放。
检索了 Medline、EMBASE 和 Cochrane 数据库,以比较远程缺血预处理(无论时机如何)与无预处理的随机临床试验。两名调查员独立选择合适的试验、评估试验质量并提取数据。共纳入了 23 项涉及心脏手术(15 项研究)、经皮冠状动脉介入治疗(4 项研究)和血管手术(4 项研究)的患者的研究,共纳入了 1878 例患者。与无预处理相比,远程缺血预处理并未降低死亡率(比值比 1.22 [95%置信区间 0.48, 3.07])或主要不良心血管事件(0.65 [0.38, 1.14])。然而,远程缺血预处理降低了心肌梗死的发生率(0.50 [0.31, 0.82]),同时也降低了肌钙蛋白峰值释放(标准化均数差-0.28 [-0.47, -0.09])。
没有证据表明远程缺血预处理可以降低与缺血事件相关的死亡率,也不能降低主要不良心血管事件的发生率。然而,远程缺血预处理确实降低了围手术期心肌梗死的发生率以及肌钙蛋白的释放。